BACKGROUND: The recurrence of hepatitis C viral infection is common after liver transplant, and achieving a sustained virological response to antiviral treatment is desirable for reducing the risk of graft loss and improving patients' survival. AIM: To investigate the long-term maintenance of sustained virological response in liver transplant recipients with hepatitis C recurrence. METHODS: 436 Liver transplant recipients (74.1% genotype 1) who underwent combined antiviral therapy for hepatitis C recurrence were retrospectively evaluated. RESULTS: The overall sustained virological response rate was 40% (173/436 patients), and the mean follow-up after liver transplantation was 11±3.5 years (range, 5-24). Patients with a sustained virological response demonstrated a 5-year survival rate of 97% and a 10-year survival rate of 93%; all but 6 (3%) patients remained hepatitis C virus RNA-negative during follow-up. Genotype non-1 (p=0.007), treatment duration >80% of the scheduled period (p=0.027), and early virological response (p=0.002), were associated with the maintenance of sustained virological response as indicated by univariate analysis. Early virological response was the only independent predictor of sustained virological response maintenance (p=0.008). CONCLUSIONS: Sustained virological response achieved after combined antiviral treatment is maintained in liver transplant patients with recurrent hepatitis C and is associated with an excellent 5-year survival.

Long-term maintenance of sustained virological response in liver transplant recipients treated for recurrent hepatitis C / Francesca Romana Ponziani;Raffaella Viganò;Rosa Maria Iemmolo;Maria Francesca Donato;Maria Rendina;Pierluigi Toniutto;Luisa Pasulo;Maria Cristina Morelli;Patrizia Burra;Lucia Miglioresi;Manuela Merli;Daniele Di Paolo;Stefano Fagiuoli;Antonio Gasbarrini;Maurizio Pompili;L. Belli;G.E. Gerunda;M. Marino;R. Montalti;F. Di Benedetto;N. De Ruvo;C. Rigamonti;M. Colombo;G. Rossi;A. Di Leo;L. Lupo;V. Memeo;R. Bringiotti;M. Zappimbulso;D. Bitetto;V. Vero;M. Colpani;E. Fornasiere;A.D. Pinna;M.C. Morelli;V. Bertuzzo;E. De Martin;M. Senzolo;G.M. Ettorre;U. Visco-Comandini;G. Antonucci;M. Angelico;G. Tisone;V. Giannelli;M. Giusto. - In: DIGESTIVE AND LIVER DISEASE. - ISSN 1590-8658. - ELETTRONICO. - 46:(2014), pp. 440-445. [10.1016/j.dld.2014.01.157]

Long-term maintenance of sustained virological response in liver transplant recipients treated for recurrent hepatitis C

A. D. Pinna;V. Bertuzzo;
2014

Abstract

BACKGROUND: The recurrence of hepatitis C viral infection is common after liver transplant, and achieving a sustained virological response to antiviral treatment is desirable for reducing the risk of graft loss and improving patients' survival. AIM: To investigate the long-term maintenance of sustained virological response in liver transplant recipients with hepatitis C recurrence. METHODS: 436 Liver transplant recipients (74.1% genotype 1) who underwent combined antiviral therapy for hepatitis C recurrence were retrospectively evaluated. RESULTS: The overall sustained virological response rate was 40% (173/436 patients), and the mean follow-up after liver transplantation was 11±3.5 years (range, 5-24). Patients with a sustained virological response demonstrated a 5-year survival rate of 97% and a 10-year survival rate of 93%; all but 6 (3%) patients remained hepatitis C virus RNA-negative during follow-up. Genotype non-1 (p=0.007), treatment duration >80% of the scheduled period (p=0.027), and early virological response (p=0.002), were associated with the maintenance of sustained virological response as indicated by univariate analysis. Early virological response was the only independent predictor of sustained virological response maintenance (p=0.008). CONCLUSIONS: Sustained virological response achieved after combined antiviral treatment is maintained in liver transplant patients with recurrent hepatitis C and is associated with an excellent 5-year survival.
2014
Long-term maintenance of sustained virological response in liver transplant recipients treated for recurrent hepatitis C / Francesca Romana Ponziani;Raffaella Viganò;Rosa Maria Iemmolo;Maria Francesca Donato;Maria Rendina;Pierluigi Toniutto;Luisa Pasulo;Maria Cristina Morelli;Patrizia Burra;Lucia Miglioresi;Manuela Merli;Daniele Di Paolo;Stefano Fagiuoli;Antonio Gasbarrini;Maurizio Pompili;L. Belli;G.E. Gerunda;M. Marino;R. Montalti;F. Di Benedetto;N. De Ruvo;C. Rigamonti;M. Colombo;G. Rossi;A. Di Leo;L. Lupo;V. Memeo;R. Bringiotti;M. Zappimbulso;D. Bitetto;V. Vero;M. Colpani;E. Fornasiere;A.D. Pinna;M.C. Morelli;V. Bertuzzo;E. De Martin;M. Senzolo;G.M. Ettorre;U. Visco-Comandini;G. Antonucci;M. Angelico;G. Tisone;V. Giannelli;M. Giusto. - In: DIGESTIVE AND LIVER DISEASE. - ISSN 1590-8658. - ELETTRONICO. - 46:(2014), pp. 440-445. [10.1016/j.dld.2014.01.157]
Francesca Romana Ponziani;Raffaella Viganò;Rosa Maria Iemmolo;Maria Francesca Donato;Maria Rendina;Pierluigi Toniutto;Luisa Pasulo;Maria Cristina Morelli;Patrizia Burra;Lucia Miglioresi;Manuela Merli;Daniele Di Paolo;Stefano Fagiuoli;Antonio Gasbarrini;Maurizio Pompili;L. Belli;G.E. Gerunda;M. Marino;R. Montalti;F. Di Benedetto;N. De Ruvo;C. Rigamonti;M. Colombo;G. Rossi;A. Di Leo;L. Lupo;V. Memeo;R. Bringiotti;M. Zappimbulso;D. Bitetto;V. Vero;M. Colpani;E. Fornasiere;A.D. Pinna;M.C. Morelli;V. Bertuzzo;E. De Martin;M. Senzolo;G.M. Ettorre;U. Visco-Comandini;G. Antonucci;M. Angelico;G. Tisone;V. Giannelli;M. Giusto
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/385327
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 2
social impact